2020 Announcements

CLINUVEL
Posted by CLINUVEL
July 8, 2020

Lapse and Forfeit of Unlisted Conditional Performance Rights

CLINUVEL PHARMACEUTICALS LTD wishes to advise in accordance with the terms and...

Read More
CLINUVEL
Posted by CLINUVEL
February 25, 2020

Appendix 3B and Appendix 3Y Withdrawn

Melbourne, Australia 25 February 2020 CLINUVEL PHARMACEUTICALS LTD (“Company”) withdraws the Appendix...

Read More
CLINUVEL
Posted by CLINUVEL
February 24, 2020

CLINUVEL Expands Singapore Laboratories

CLINUVEL PHARMACEUTICALS LTD today announced that it is investing in the further...

Read More
CLINUVEL
Posted by CLINUVEL
February 10, 2020

Request for FDA Guidance Meeting SCENESSE® in Vitiligo

CLINUVEL requests Type C Guidance meeting to progress the clinical program in...

Read More
CLINUVEL
Posted by CLINUVEL
February 3, 2020

Australian TGA commences SCENESSE® review

EXECUTIVE SUMMARY SCENESSE® (afamelanotide 16mg) technology review starts in Australia for rare...

Read More
CLINUVEL
Posted by CLINUVEL
January 31, 2020

Appendix 4C

CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering...

Read More
CLINUVEL
Posted by CLINUVEL
January 29, 2020

CLINUVEL Kommuniqué I

Sehr geehrte Aktionärinnen und Aktionäre, liebe Freunde Im Namen des CLINUVEL-Ausschusses wünsche...

Read More
CLINUVEL
Posted by CLINUVEL
January 16, 2020

CLINUVEL Newsletter

Dear shareholders, friends On behalf of the CLINUVEL Board, I wish you...

Read More
We use cookies to give you the best experience.